J&J's Drugs, Devices Drive Profit Above Wall Street Expectations [BNN Bloomberg (Canada)]
Kenvue Inc. (KVUE)
Company Research
Source: BNN Bloomberg
Adjusted profit for the quarter was $2.29 a share, the New Brunswick, New Jersey-based company said Tuesday in a statement, while analysts had estimated $2.28. J&J's med-tech revenue reached $7.67 billion, and strong sales of its top-selling psoriasis drug Stelara helped its pharma unit. J&J has narrowed its focus on high-margin opportunities in its pharma and devices businesses after spinning off its less-profitable consumer unit as Kenvue Inc. Investors are eager for a quick transition as the drugmaker faces a steep drop in sales for Stelara when cheaper biosimilar versions enter the US market early next year. Sales of hip equipment were $398 million, while knee devices sold $387 million, both beating Street expectations. The devices' sales signal whether a recent uptick in procedures that had fallen off during Covid, and a move away from hospitals and toward ambulatory surgery centers, will continue to drive growth in the sector. The shares fell 0.5% before US markets opened
Show less
Read more
Impact Snapshot
Event Time:
KVUE
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
KVUE alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
KVUE alerts
High impacting Kenvue Inc. news events
Weekly update
A roundup of the hottest topics
KVUE
News
- Kenvue Declares Quarterly Cash DividendBusiness Wire
- J&J Profit Beats Estimates as Pharma Sales Edge Out Street [BNN Bloomberg (Canada)]BNN Bloomberg
- Zimbabwe Recalls Tainted J&J's Cough Syrup Sold in Six African Nations [BNN Bloomberg (Canada)]BNN Bloomberg
- J&J's Tainted Cough Syrup Was Sold in Six African Countries [BNN Bloomberg (Canada)]BNN Bloomberg
- Kenvue Inc. (NYSE: KVUE) is now covered by analysts at Sanford C. Bernstein. They set an "underperform" rating and a $18.00 price target on the stock.MarketBeat
KVUE
Earnings
- 2/8/24 - Beat
KVUE
Sec Filings
- 4/10/24 - Form ARS
- 4/10/24 - Form DEFA14A
- 4/10/24 - Form DEF
- KVUE's page on the SEC website